IPilogue

DECEMBER 3, 2021

As part of the course requirements, students were asked to write a blog on a topic of their choice. The justification for the prohibition is agreeable: fear of patent infringement should not deter medical practitioners from applying their exercise of skill and judgment (see Janssen v Mylan at para 53 ).

Intellectual Property Law 106

Intellectual Property Law Patent Infringement Intellectual Property Law 106

Patently-O

NOVEMBER 11, 2022

The scope afforded to chemical genus claims under 35 USC § 112(a)’s enablement and written description requirements has been hot topic recently (at least in certain quarters). Novartis Pharmaceuticals Corp., Janssen Biotech, Inc. , See, for example, Ajinomoto Co. Int’l Trade Comm’n , 932 F.3d 3d 1342 (Fed. Baxalta Inc. ,

Inventor 48

Inventor Invention Patent Reporting 48

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

Regeneron Pharmaceuticals, Inc., The most challenged patents relate to aflibercept, held by Regeneron and sold under the trade names Eylea® and Zaltrap®, and tocilizumab, held by Chugai Pharmaceutical Co. Denials of institution – particularly the extent to which they are reviewable – have long been a contentious topic for the PTAB.

Reporting 52

Reporting Art Invention Patent 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., The Preserve Access to Affordable Generics and Biosimilars Act (S.

Litigation 52

Litigation Settlement Patent Marketing 52